Table 1.
Summary of patient and lesions characteristics n (%)
| Characteristics | |||
| Age (yr) | Mean ± SD | 60.3 ± 13.6 | |
| Median | 61.5 | ||
| IQR | 51-71 | ||
| Range | 17-86 | ||
| Gender | Female | 22 (33.3) | |
| Male | 44 (66.7) | ||
| Race | Black | 7 (10.6) | |
| White | 54 (81.8) | ||
| Other | 5 (7.6) | ||
| Lesion type | Esophagus | All | 40 (60.6) |
| Normal/Benign | 12 (30) | ||
| LGD | 13 (32.5) | ||
| HGD | 8 (20) | ||
| Neoplastic | 7 (17.5) | ||
| Gastric | All | 7 (10.6) | |
| Normal/Benign | 2 (28.6) | ||
| LGD | 1 (14.3) | ||
| HGD | 2 (28.6) | ||
| Neoplastic | 2 (28.6) | ||
| Colonic | All | 1 (1.5) | |
| Normal/Benign | 0 | ||
| LGD | 0 | ||
| HGD | 1 (100) | ||
| Neoplastic | 0 | ||
| Ampulla | All | 3 (4.5) | |
| Normal/Benign | 2 (66.7) | ||
| LGD | 0 | ||
| HGD | 1 (33.3) | ||
| Neoplastic | 0 | ||
| Pancreaticobiliary | All | 15 (22.7) | |
| Normal/Benign | 4 (26.7) | ||
| LGD | 0 | ||
| HGD | 1 (6.7) | ||
| Neoplastic | 10 (66.7) | ||
| Indication for pCLE | Indeterminate lesion | 34 (51.5) | |
| Surveillance | 18 (27.3) | ||
| Targeted biopsy ± therapy | 13 (19.7) | ||
| Other | 1 (1.5) |
pCLE: Probe-based confocal laser endomicroscopy.